Advanced search×
×

Oncotarget

Electronic ISSN
1949-2553

  1. Chemoprevention of metastasis.

    Oncotarget 5(16):6556 (2014) PMID 25179303

    Comment on: Xu L, et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 2014 25; 6:242ra84.
  2. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis.

    Oncotarget 5(16):6983 (2014) PMID 25149530

    We screened miRNAs associated with drug resistance in pancreatic cancer, and identified a panel of miRNAs dysregulated in gemcitabine-resistance pancreatic cancer cells, including 13 downregulated miRNAs and 20 upregulated miRNAs. Further studies focusing on miR-497 demonstrated that miR-497 suppres...
  3. A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling.

    Oncotarget 5(16):6947 (2014) PMID 25216520

    We exposed 20 tumor cell lines to repeated periods of hypoxia/reoxygenation to determine a transcriptomic CycHyp signature and used clinical data sets from 2,150 breast cancer patients to estimate a prognostic Cox proportional hazard model to assess its prognostic performance. The CycHyp prognostic...
  4. Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor bind...

    Oncotarget 5(15):6168 (2014) PMID 25026280

    We investigated the potential regulatory roles of risk variants in two prostate cancer GWAS datasets by their interactions with expression quantitative trait loci (eQTL) and/or transcription factor binding sites (TFBSs) in three populations. Our results indicated that the moderately associated GWAS...
  5. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles.

    Oncotarget 5(15):6453 (2014) PMID 25071019

    We reported that gold nanoparticles (AuNPs) inhibit ovarian tumor growth and metastasis in mice by reversing epithelial-mesenchymal transition (EMT). Since EMT is known to confer drug resistance to cancer cells, we wanted to investigate whether anti-EMT property of AuNP could be utilized to sensitiz...
  6. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma.

    Oncotarget 5(14):5209 (2014) PMID 24970819

    We employed tissue microarrays containing >300 unique RCC cases and adjacent benign renal tissue to determine NY-ESO-1 expression using a quantitative immunofluorescence method. In addition, we studied NY-ESO-1 expression in 35 matched primary and metastatic RCC specimens to assess concordance betwe...
  7. Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis.

    Oncotarget 5(14):5510 (2014) PMID 24980816

    We elucidated novel intracellular BSP functions by a conditional knockdown of BSP. Conditional MDA-MB-231 subclones were equipped with a novel gene expression cassette containing a tet-reg-ulated miRNA providing knockdown of BSP production. These clones were used to assess the effect of BSP on morph...
  8. Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/β-catenin signalling in pancreatic adenocarcino...

    Oncotarget 5(14):5335 (2014) PMID 24977327

    We evaluated the expression of Gal-4 in PDAC tissues selected according to their lymph node metastatic status (N0 vs. N1), and investigated the therapeutic potential of targeting the cross-link with the Wnt signaling pathway in primary PDAC cells. Analysis of Gal-4 expression in PDACs showed high ex...
  9. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis.

    Oncotarget (2011) PMID 21606550

    We performed an absolute quantification of PKM1 and PKM2 splice isoforms in 25 human malignant cancers, 6 benign oncocytomas, tissue matched controls, and several cell lines. PKM2 was the prominent isoform in all analyzed cancer samples and cell lines. However, this PKM2 dominance was not a result o...
  10. EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer.

    Oncotarget 5(16):7172 (2014) PMID 25115397

    We demonstrate that ID4 promoter methylation is initiated by EZH2 dependent tri-methylation of histone 3 at lysine 27 (H3K27me3). ID4 expressing (LNCaP) and non-expressing (DU145 and C81) prostate cancer cell lines were used to investigate EZH2, H3K27me3 and DNMT1 enrichment on ID4 promoter by Chrom...